Table 1.
Summary of marker expression in MV-like fractions obtained from different specimens
| Vesicle Type | Protein | Microvesicles Obtained from | ||
|---|---|---|---|---|
| GBM8 Cells | GL261 Cells | Human Plasma | ||
| All vesicles | CD9 | 0.26 | 0.02 | 0.12 |
| CD63 | 0.13 | 0.02 | 0.09 | |
| CD81 | 0.49 | 0.67 | 0.14 | |
| TSG101 | 0.43 | 0.15 | 0.11 | |
| Alix | 0.06 | 0.1 | 0.41 | |
| CD40 | 0.09 | 0.1 | 0.1 | |
| Arf6 | 0.05 | 0.12 | 0.29 | |
| VAMP-3 | 0.05 | 0.04 | 0.09 | |
| IDH1WT | 0.48 | 0.22 | 0.03 | |
| Integrin beta 1 | 0.52 | 0.73 | 0.26 | |
| Tumor vesicles | EGFR | 0.32 | 0.11 | See Fig. 4 |
| EGFRvIII | 0.12 | 0.07 | ||
| IDH1-R132H | 0 | NA | ||
| EpCAM | 0.06 | 0.09 | ||
The table summarizes the fractions of MV-like vesicles that are positive for a given protein across cell lines and human samples (n = 10). For example, the putative ubiquitous MV biomarker integrin beta 1 was present in only 52% of GBM8. In GL261 cells it was present in 73% of vesicles but in primary human samples only in 26% of MV-like vesicles. In human samples, this fraction was lower (26%). IDH1-R132H was not detected in any of the samples and all human tumors were IDH wildtype by sequencing. WT = wildtype; NA = no mouse antibody available.